Denali Therapeutics Inc (DNLI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has a cash flow conversion efficiency ratio of -0.142x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-131.20 Million) by net assets ($926.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Denali Therapeutics Inc (DNLI) defensive interval to measure how many days the company can operate on defensive assets alone.
Denali Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Denali Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Denali Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Denali Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Great Wall Military Industry Co Ltd
SHG:601606
|
-0.010x |
|
GZ Port
SHG:601228
|
0.010x |
|
Beijing Sinnet Technology Co Ltd
SHE:300383
|
0.033x |
|
New Hope Corporation Ltd
AU:NHC
|
0.071x |
|
Aneka Tambang (Persero) TBK (PT)
AU:ATM
|
-0.079x |
|
Huhtamaki Oyj
HE:HUH1V
|
0.122x |
|
NBCC (India) Limited
NSE:NBCC
|
-0.384x |
|
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
|
0.008x |
Annual Cash Flow Conversion Efficiency for Denali Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Denali Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see DNLI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.01 Billion | $-412.60 Million | -0.407x | -43.94% |
| 2024-12-31 | $1.23 Billion | $-347.69 Million | -0.283x | +18.57% |
| 2023-12-31 | $1.03 Billion | $-357.99 Million | -0.347x | -47.92% |
| 2022-12-31 | $1.04 Billion | $-244.72 Million | -0.235x | -6.87% |
| 2021-12-31 | $962.29 Million | $-211.39 Million | -0.220x | -160.73% |
| 2020-12-31 | $1.15 Billion | $416.15 Million | 0.362x | +194.23% |
| 2019-12-31 | $394.89 Million | $-151.58 Million | -0.384x | -518.83% |
| 2018-12-31 | $546.85 Million | $50.12 Million | 0.092x | +155.70% |
| 2017-12-31 | $465.80 Million | $-76.64 Million | -0.165x | +42.13% |
| 2016-12-31 | $254.52 Million | $-72.36 Million | -0.284x | -129.53% |
| 2015-12-31 | $-15.63 Million | $-15.05 Million | 0.963x | -- |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 pr… Read more